Loss of NIS protein expression at the basolateral membrane of thyrocytes is a well-accepted precursor for reduced effectiveness of I131 therapy, as demonstrated in poorly differentiated and undifferentiated thyroid cancers [49, 50]. The gene discussed is SLC5A5; the disease is thyroid gland carcinoma.